At this moment, no ICIs have been approved for prostate cancer, and most clinical trials, including a phase III study with ICIs, CTLA-4 and PD-1/PD-L1 inhibitors, are disappointing26. This evidence concerns the gene PDCD1 and prostate carcinoma.